tiprankstipranks
TipRanks’ All-Star Analyst – Who is the Best on MRK Stock?
Stock Analysis & Ideas

TipRanks’ All-Star Analyst – Who is the Best on MRK Stock?

Story Highlights

Analyst Robyn Karnauskas of research firm Truist Financial is the Most Accurate and Most Profitable analyst for MRK stock over a one-year time frame. Let’s take a look at the All-star analyst’s performance in detail.

The TipRanks All-star Analyst of the Day title goes to Robyn Karnauskas of research firm Truist Financial. Remarkably, Karnauskas ranks #945 out of the 8,688 Wall Street analysts tracked by TipRanks. One of the key stocks in her coverage is Merck & Company (NYSE:MRK), for which she is the Most Accurate and Most Profitable analyst.

Pick the best stocks and maximize your portfolio:

Merck is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of several healthcare products.

Most Profitable and Accurate Analyst on MRK Stock 

When we look at Karnauskas’ recommendation for MRK stock, we see that over the past year, Karnauskas has had a 100% success rate on the stock. Plus, she has earned an impressive average return of 21.78% in the said period.

On an overall basis, copying Karnauskas’ trades and holding them for a year would give you an average return of 6.9%, with 50% of your trades generating a profit.

Not Just MRK 

Karnauskas primarily focuses on covering the healthcare sector in the U.S. market. Importantly, her most profitable rating to date was a Buy on Bioxcel Therapeutics (BTAI). This biopharmaceutical company uses artificial intelligence to advance the development of novel medicines across various therapeutic areas. The analyst earned a massive 800% return on the call between November 12, 2019, and November 12, 2020.

Following phenomenally successful analysts’ ratings can add profit to your portfolio. Find the best analyst to follow for any stock by scrolling down to the “Best Analyst Covering” feature on its Analyst Forecast page.

To follow the best Wall Street analysts, take a look at the list of Top Analysts on TipRanks. 

Disclosure

Related Articles
TheFlyMerck reinstated with a Buy at BofA
TheFlyIdeaya Biosciences doses first patient in IDE161, Keytruda combination trial
TheFlyMerck price target lowered to $125 from $135 at Berenberg
Go Ad-Free with Our App